P695 Vedolizumab induction and maintenance though levels and long-term clinical and biochemical status in inflammatory bowel disease
ECCO'20 Vienna
2020
P696 The usefulness to treatment enhancement for the patients of ulcerative colitis with clinical remission diagnosed as Mayo endoscopic subscore 1
ECCO'20 Vienna
2020
P697 Efficacy and safety of ustekinumab in Crohn’s disease: A real-world study from Australia
ECCO'20 Vienna
2020
P699 The concordance of Short Form-36 Health Survey scores with Mayo scores in the tofacitinib ulcerative colitis clinical programme
ECCO'20 Vienna
2020
P700 Effect of vitamin D in disease activity score and clinical relapse in patients with inflammatory bowel disease: A systematic review and meta-analysis
ECCO'20 Vienna
2020
P702 Treatment decisions in older inflammatory bowel disease patients: Applying gut feeling in an evidence-based era? A qualitative study
ECCO'20 Vienna
2020
P704 The biennial direct pharmaceutical costs per treatment with biologics for the inflammatory bowel disease in Greece: A comparative calculation study
ECCO'20 Vienna
2020
P705 Dietary practices and beliefs of patients with older-onset inflammatory bowel disease: A prospective UK study
ECCO'20 Vienna
2020
P706 Adalimumab drug levels at secondary loss of response in Crohn’s disease; are we aiming high enough? A retrospective, international multi-centre study
ECCO'20 Vienna
2020
P707 Anti-TNFα therapy has no effect on bone mineral density in younger patients with inflammatory bowel disease: A single-centre observational study
ECCO'20 Vienna
2020
P708 The effect of psychotherapy on quality of life in inflammatory bowel disease patients: A systematic literature review
ECCO'20 Vienna
2020
P709 Is azathioprine safe as long-term treatment in paediatric patients with inflammatory bowel disease?
ECCO'20 Vienna
2020
P710 The influence of probiotics to the efficacy of 5-ASA for the patients of ulcerative colitis
ECCO'20 Vienna
2020